Nothing shifted during shipping, and the vial arrived undamaged with no signs of mishandling
Aetna does not provide care or guarantee access to health services
KFF Health Tracking Poll data from November 2025 found that 12% of US adults are currently taking a GLP-1 drug (approximately 31 million Americans by population extrapolation), up from 6% in May 2024
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
Biological activity of AC3174, a peptide analog of exendin-4
Because NACET (but not NAC) may pass the blood-brain barrier and provide a variety of beneficial antioxidant actions, NACET is present in the cells of various tissues, including the brain
